These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 8455665)

  • 1. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
    Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
    N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses.
    Campora E; Giudici S; Merlini L; Rubagotti A; Rosso R
    Am J Clin Oncol; 1994 Dec; 17(6):522-6. PubMed ID: 7977174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
    Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
    J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
    Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
    J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
    Barrenetxea G; Schneider J; Centeno MM; Romero H; de la Rica M; Rodríguez-Escudero FJ
    Cancer Chemother Pharmacol; 1996; 38(5):471-5. PubMed ID: 8765442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
    J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
    Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
    Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
    Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
    Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
    Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
    J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
    Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
    J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
    J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Optimal control by ondansetron of acute and prolonged emesis induced by chemotherapy without cisplatin].
    Harousseau JL
    Bull Cancer; 1996 Jan; 83(1):71-76. PubMed ID: 8672859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis.
    Sabbatini R; Federico M; Baldini L; Barbieri F; Maiolo MT; Silingardi V
    Haematologica; 1995; 80(5):416-20. PubMed ID: 8566881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.